Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Current nucleic acid amplification methods to detect Mycobacterium tuberculosis are complex, labor-intensive, and technically challenging. We developed and performed the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay, an integrated hands-free sputum-processing and real-time PCR system with rapid on-demand, near-patient technology, to simultaneously detect M. tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4.5 genomes per reaction. Studies using sputum spiked with known numbers of M. tuberculosis CFU predicted a clinical LOD of 131 CFU/ml. Killing studies showed that the assay's buffer decreased M. tuberculosis viability by at least 8 logs, substantially reducing biohazards. Tests of 23 different commonly occurring rifampin resistance mutations demonstrated that all 23 (100%) would be identified as rifampin resistant. An analysis of 20 nontuberculosis mycobacteria species confirmed high assay specificity. A small clinical validation study of 107 clinical sputum samples from suspected tuberculosis cases in Vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively. M. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. A study of 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in Uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance. Rifampin resistance was excluded in 54/55 (98.2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that Xpert does not cross‐react with other mycobacterial species (Blakemore 2010; Helb 2010).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Helb 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This represents a substantial reduction in diagnostic delay, thereby permitting real-time decision making and planning of treatment (5).”
From Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens (2011) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies reported 98–100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Such cases (Xpert-positive but culture-negative) are likely to be true TB positives as corroborated by the high specificity [14,18] and by the fact that the procedure is less prone to contamination due to the closed reaction chamber (real-time PCR technology) of Xpert.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
Sexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,072
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A., & Berman, S. M. (2007) · Clinical Infectious Diseases · doi:10.1086/511430 · Cited by 1,973
The association for the advancement of medical instrumentation
(1974) · Ultrasound in Medicine & Biology · doi:10.1016/0301-5629(74)90035-0 · Cited by 1,031
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Molecular Detection of Antimicrobial Resistance
Fluit, A. C., Visser, M. R., & Schmitz, F.-J. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.836-871.2001 · Cited by 525 · cited 1×
“tuberculosis detection (15), this assay was too complex and too prone to operator errors, sample cross-contamination, and biohazards for rapid near-patient use.”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 3×
“Truly rapid results for drug susceptibility tests are particularly important in the management of drug-resistant tuberculosis (13).”
BackgroundMicroscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., Sanchez, E., Piñedo, Y., Saravia, J. C., Salazar, C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055524 · Cited by 468
Cited by
Items 501–600 of 940
Byashalira, K. C., Mbelele, P. M., Semvua, H. H., Chilongola, J. O., Semvua, S. K., Liyoyo, A., Mmbaga, B. T., Mfinanga, S., Moore, C. C., Heysell, S. K., et al. (2019) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_135_19 · Cited by 12
“proportion of PLHIV diagnosed and rapidly initiated on anti‐TB treatment, and an improved yield of urine LF‐LAM and sputum Xpert MTB/RIF in combination compared to sputum Xpert MTB/RIF alone.[15] These findings are in keeping with a report from South Africa that implementation of LF‐LAM along with Xpert MTB/RIF not on…”
ResultZewdie, O., Dabsu, R., Tola, E. K., & Befikadu, D. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s274589 · Cited by 13
Tuberculosis del sistema nervioso central
Edna González, S., Camila García, A., María Gabriela Ortiz, P., & Pérez, E. S. (2021) · Acta neurológica colombiana · doi:10.22379/24224022338 · Cited by 11
Adewusi, O. O., Waldner, C., Hanington, P. C., Hill, J. E., Freeman, C. N., & Otto, S. J. G. (2024) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/10406387241235968 · Cited by 12
Chilambi, G. S., Reiss, R., Daivaa, N., Banada, P. P., de Vos, M., Penn‐Nicholson, A., & Alland, D. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02403-24 · Cited by 13
Self-citationMogashoa, T., Loubser, J., Choga, O. T., Ngom, J. T., Choga, W. T., Mbulawa, M. B., Molefi, T., Stephen, O., Makhondo, T., Seru, K., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1535160 · Cited by 11
Kohli, M., Inbaraj, L. R., Salomon, A., Scandrett, K., Korobitsyn, A., Ismail, N. A., Srinivasalu, V. A., Daniel, J., Steingart, K. R., & Takwoingi, Y. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012768.pub4 · Cited by 14
Cartridge based nucleic acid amplification test is superior in diagnosing lymphnode tuberculosis
Chandrappa, N., Rastogi, A., & Bhatnagar, A. K. (2018) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2018.04.001 · Cited by 11
Wakode, P., Siddaiah, N., Netravathi, M., & Bahubali, V. K. H. (2022) · Journal of Neurosciences in Rural Practice · doi:10.1055/s-0041-1742138 · Cited by 11
Bokop, C., Faye, L. M., & Apalata, T. R. (2023) · Pathogens · doi:10.3390/pathogens12070909 · Cited by 11
“established that the Xpert MTB/RIF assay has a limit of detection (LOD), defined as the minimum number of bacilli that can be detected with 95% confidence of 131 CFU per ml of clinical sputum, this was not observed in our study [14].”
ResultA Differential Fluorescent Receptor for Nucleic Acid Analysis
Bengtson, H. N., & Kolpashchikov, D. M. (2013) · ChemBioChem · doi:10.1002/cbic.201300657 · Cited by 11
Sanjuán‐Jiménez, R., de Toro-Peinado, I., Bermudez, P. G., Colmenero, J., & Morata, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143025 · Cited by 11
“[21] reported a LOD of 131 CFU/ml with sputum samples spiked withM.”
MethodHu, P., Bai, L., Liu, F., Ou, X., Zhang, Z., Yi, S., Chen, Z., Gong, D., Liu, B., Guo, J., et al. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20141004 · Cited by 11
“6–100%.(6-7,13) In our study, the sensitivity and specificity of this assay were 92.”
BackgroundWang, Q., Kontoyiannis, D. P., Li, R., Chen, W., Bu, D., & Liu, W. Y. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00604-19 · Cited by 11
“Moreover, we interpreted the sensitivity of our allele-specific real-time PCR method by using CFU counts, which are widely used in evaluating the number of viable cells of microbes (32).”
MethodHopewell, P. C., Kato‐Maeda, M., & Ernst, J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00035-x · Cited by 15
Omar, S. V., Peters, R. P. H., Ismail, N. A., Dreyer, A. W., Said, H. M., Gwala, T., Ismail, N. A., & Fourie, P. B. (2015) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2015.07.010 · Cited by 13
Gonçalves, M. G., Fukasawa, L. O., de Oliveira, R. S., Salgado, M. M., Harrison, L. H., Shutt, K. A., & Sacchi, C. T. (2012) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762012000700011 · Cited by 11
“Commercial assays, such as GeneXpert (Cepheid), which detects M. tuberculosis and resistance to RIF, demonstrated good performance with clinical specimens (Helb et al. 2010, Lawn & Nicol 2011, Zeka et al. 2011).”
MethodDetection of drug resistance in Mycobacterium tuberculosis: Methods, principles and applications
Gupta, A., & Anupurba, S. (2015) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2015.02.003 · Cited by 12
Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients
Podlekareva, D. N., Grint, D. J., Post, F. A., Mocroft, A., Panteleev, A., Miller, R. F., Miró, J. M., Bruyand, M., Furrer, H., Riekstiņa, V., et al. (2013) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0224 · Cited by 11
Khan, S. U., Rahman, H., Ayaz, S., Qasim, M., Jabbar, A., Khurshid, M., Hussain, M., Muhammad, N., Rehman, S. U., & Ali, N. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.03.005 · Cited by 11
Early Detection and Analysis of Children with Multidrug-Resistant Tuberculosis of the Spine
Arockiaraj, J., Robert, M., Rose, W., Amritanand, R., David, K. S., & Krishnan, V. (2018) · Asian Spine Journal · doi:10.31616/asj.2017.0217 · Cited by 11
“Xpert MTB/RIF, being a molecular assay, detects up to 131 cfu/mL [28].”
BackgroundMendis, C., Thevanesam, V., Kumara, A., Wickramasinghe, S., Madegedara, D., Gamage, C. D., Gordon, S. V., Suzuki, Y., Ratnatunga, C. N., & Nakajima, C. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.07.001 · Cited by 11
Valuing the use of GeneXpert test as an unconventional approach to diagnose pulmonary tuberculosis
Omar, A., Elfadl, A.-E. A., Ahmed, Y., & Hosny, M. (2019) · Egyptian Journal of Bronchology · doi:10.4103/ejb.ejb_88_18 · Cited by 11
Tiwari, K., Prasad, S., & Tanwar, R. (2020) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_52_20 · Cited by 11
“[11] Gene Xpert is DNA based and is capable of detecting 80–130 Mycobacterium tuberculosis/ml in the infected material and also detects rifampicin resistance within 2 h.[12,13] Its sensitivity was well compared to culture.”
BackgroundGeneXpert on patients with human immunodeficiency virus and smear-negative pulmonary tuberculosis
Cuong, N. K., Ngoc, N. B., Hoa, N. B., Dat, V. Q., & Nhung, N. V. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253961 · Cited by 14
Dharan, N. J., Amisano, D., Mboowa, G., Ssengooba, W., Blakemore, R., Kubiak, R. W., Armstrong, D. T., Jones, M., Manabe, Y. C., Joloba, M. L., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.03619-14 · Cited by 11
“In general, SR is thought to inactivate PCR inhibitors (2, 8) and is not thought to inhibit the Xpert test at the recommended SR concentrations, but this possibility should be investigated in further studies.”
BackgroundMethodSelf-citationWhitfield, N. N., Martinez, R. M., & Wolk, D. M. (2016) · Wiley eBooks · doi:10.1002/9781119021872.ch24 · Cited by 11
Wang, Y., Ma, Z., Liu, Z., Dong, X., Shu, W., Wei, M., Cui, J., Shu, W., Li, R., Jing, W., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106517 · Cited by 10
Maleki, M. R. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s542287 · Cited by 13
Comparison of Two Molecular Assays For Detecting Smear Negative Pulmonary Tuberculosis.
Li, Q., Bao, X. D., Liu, Y., Ou, X. C., Pang, Y., & Zhao, Y. (2016) · PubMed · doi:10.3967/bes2016.032 · Cited by 10
“Because of its rapid detections for MTBC and the resistance to rifampin, Xpert MTB/RIF (Cepheid, USA) is widely used in the world([3-4]).”
BackgroundSharma, M., Broor, S., Maheshwari, M., & Sudan, D. (2022) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2022.04.006 · Cited by 10
Torokaa, P. R., Kileo, H., Urio, L., Mbwana, M. R., Mbwana, M. R., Ntibabara, S. S., Kimambo, J., Seleman, P., Franklin, C., Balama, R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296563 · Cited by 10
“Almost 96.1% of rifampicin-resistant MTB strains have rpoB mutations [7].”
BackgroundInfluentialNouveaux tests pour le diagnostic de la tuberculose
Ninet, B., Roux-Lombard, P., Schrenzel, J., & Janssens, J.-P. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.12.012 · Cited by 15
Allen, V., Nicol, M. P., & Tow, L. A. (2015) · Research and Reviews: Journal of Microbiology and Biotechnology · Cited by 10
Rao, P., Chawla, K., Shenoy, V. P., & Mukhopadhyay, C. (2016) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2016.08.002 · Cited by 10
Kostera, J., Leckie, G. W., Abravaya, K., & Wang, H. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s158953 · Cited by 10
“The RT MTB RIF/INH uses eight probes to detect RIF resistance, while Xpert uses five probes (A–E).(7,13) 28 samples had RT”
Maslow, M. J., & Portal‐Celhay, C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00027-8 · Cited by 12
Iem, V., Chittamany, P., Suthepmany, S., Siphanthong, S., Somphavong, S., Kontogianni, K., Dodd, J., Khan, J. A. M., Domínguez, J., Wingfield, T., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000116 · Cited by 11
“6 cfu/ml) [21] is lower than for Xpert MTB/RIF’s (131 cfu/ml) [22], thus reducing the risk of the diluted TB DNA falling below the detection limit.”
BackgroundEkwueme, C., Otu, A. A., Chinenye, S., Unachukwu, C., Oputa, R. N., Korubo, I. F., & Enang, O. (2016) · Clinical Case Reports · doi:10.1002/ccr3.542 · Cited by 10
“Xpert has the added advantage of detecting both TB and rifampicin resistance [20] and provides results in a little as 2 h.”
BackgroundGanguly, J., Ray, S., Nandi, S., Halder, S., Kundu, S., & Mandal, A. (2015) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2015/692 · Cited by 10
GeneXpert Technology for the diagnosis of HIV-associated tuberculosis: Is scale-up worth it?
Saeed, M., Hussain, S., Riaz, S., Rasheed, F., Ahmad, M., Iram, S., Arif, M., Rahmani, T. H., & Anwar, A. I. (2020) · Open Life Sciences · doi:10.1515/biol-2020-0052 · Cited by 10
Ali, R. H., Ibrahim, N. Y., Elegail, A., Eltohami, N. A. M., Ebraheem, R. S. M., Ahmed, S. F. M., Ahmed, H., Nour, E. O. M., Eldirdery, M. M., & Musa, H. H. (2017) · Asian Pacific Journal of Tropical Disease · doi:10.12980/apjtd.7.2017d6-442 · Cited by 10
“assays have been used to predict drug resistance in clinical specimens within one working day and are potentially the most rapid methods[6-10].”
MethodClinical Laboratory Diagnostics for Mycobacterium tuberculosis
Esther, N., & Nancy, L. P. (2012) · InTech eBooks · doi:10.5772/30972 · Cited by 9
Hussain, S., Sultan, S., Riaz, S., Hussain, H., Javed, H., & Mazhar, R. (2024) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.18945 · Cited by 9
“Furthermore, Xpert (MTB/RIF) is easily placed in remote peripheral health settings to diagnose TB and drug resistance [14].”
BackgroundLee, A. S. G., & Ong, D. C. T. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.94 · Cited by 9
Maschmann, R. D. A., Verza, M., Silva, M. S., Sperhacke, R. D., Ribeiro, M. O., Suffys, P. N., Gomes, H. M., Tortoli, E., Marcelli, F., Zaha, A., et al. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000200004 · Cited by 10
“Recently, a novel automated molecular test, Xpert MTB/RIF, used a hemi-nested real-time reaction PCR assay to amplify M. tuberculosis specific sequence of the rpoB gene (Boehme et al. 2010, Helb et al. 2010).”
MethodPeng, A., Yang, A., Li, S.-J., Qiu, Q., Yang, S., & Chen, Y. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9304 · Cited by 9
“The GX assay was performed according to the protocol of a previous study (16).”
MethodDESIGN OF MEMS BASED MICROCANTILEVER FOR TUBERCULOSIS DETECTION
Saranya, R., Saranya, K., Chandra Devi, K., & Sundaram, N. M. (2011) · Cited by 9
Atypical presentation of aural tuberculosis with complication
Singh, A. K., Irugu, D. V. K., Verma, H., & Thakar, A. (2018) · BMJ Case Reports · doi:10.1136/bcr-2017-222482 · Cited by 9
Effectiveness of Contact Tracing of Index Tuberculosis Cases in Nigeria
Okorie, O., Okezie, I., Ahukanna, J., Okebaram, C. C., Dakum, P., Agbaje, A., Ibeziako, V., Mustapha, G., Chukwueme, N., Ubochioma, E., et al. (2018) · Advances in Infectious Diseases · doi:10.4236/aid.2018.84016 · Cited by 9
“These include, sputum smear microscopy by Ziehl-Neelson technique for acid fast bacilli, rapid Xpert/MTB assay, line probe assay and sputum culture which is the gold standard but has limitation of prolonged turn-around time [45] and [46].”
MethodMicrobiología de la tuberculosis
González-Martín, J. (2014) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2014.01.001 · Cited by 9
Birungi, F. M., van Wyk, B. E., Uwimana, J., Ntaganira, J., & Graham, S. M. (2018) · Pan African Medical Journal · doi:10.11604/pamj.2018.30.39.12600 · Cited by 9
“The Xpert MTB/RIF assay can be implemented in a peripheral laboratory with a result in less than two hours that includes information on rifampicin resistance [17,20].”
BackgroundMethodLawn, S. D., & Wood, R. (2010) · Clinical Infectious Diseases · doi:10.1093/cid/ciq128 · Cited by 9
“However, when screening for TB among patients starting ART, the assay is likely to be stretched to its limits of detection (95% sensitivity in sputum samples with 131 bacilli per mL [9]).”
BackgroundMethodKurtzhals, M. L., Norman, A., Svensson, E., Lillebæk, T., & Folkvardsen, D. B. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00430-24 · Cited by 8
Wu, Q., Zhu, Y., Zhang, Y., Liu, Z., Zhang, M., Chen, J., & Wu, B. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70071 · Cited by 8
Li, T., You, R., Shen, X., Li, Z., Yang, Y., Han, Z., & Duan, X. (2025) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2025.107404 · Cited by 8
Advances in Isothermal Amplification for the Diagnosis of Tuberculosis
Jirakittiwut, N., & Ratthawongjirakul, P. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70113 · Cited by 8
Wang, J., Zhang, X., Huo, F., Lin, Q., Liu, R., Shang, Y., Yao, C., Ma, L., & Pang, Y. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.04.004 · Cited by 9
Banik, S., Ozay, B., Trejo, M., Zhu, Y., Kanna, C. R., Santellan, C. A., Shaw, B. M., Chandrasekaran, S., Chaturvedi, S., Vejar, L., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.00525-24 · Cited by 8
Self-citationClinical Features and Management of HIV/AIDS
Wood, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-5101-2.00011-x · Cited by 8
Karimi, S., Mirhendi, H., Zaniani, F. R., Manesh, S. E., Salehi, M., & Esfahani, B. N. (2017) · Advanced Biomedical Research · doi:10.4103/abr.abr_240_16 · Cited by 8
Impact of diagnostic test Xpert MTB/RIF® on health outcomes for tuberculosis
Haraka, F., Nathavitharana, R. R., Schumacher, S. G., Kakolwa, M. A., Denkinger, C. M., Gagneux, S., Reither, K., & Ross, A. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012972 · Cited by 10
Effect of history of tuberculosis on specificity of Xpert MTB/RIF
Haraka, F., Schumacher, S. G., Ross, A. J., Mantsoki, A., Gagneux, S., Reither, K., & Denkinger, C. M. (2020) · European Respiratory Journal · doi:10.1183/13993003.00343-2020 · Cited by 8
Motse, F. D. K., Nsagha, D. S., Teyim, P. M., Adiogo, D., Foko, L. P. K., Koum, D. C. K., Ngaba, G. P., & Assob, J. C. N. (2020) · Tropical Medicine & International Health · doi:10.1111/tmi.13489 · Cited by 8
“Five rpoB RRDR-specific molecular beacons are then used to detect both the presence of M. tuberculosis and mutations responsible for approximately 95% of RIF Resistance [24].”
BackgroundSingh, K., Kumari, R., Gupta, S., Tripathi, R., Srivastava, A., Shakya, V., Gupta, A., & Anupurba, S. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00463-6 · Cited by 8
“With the increasing use of the GeneXpert MTB/RIF assay for simultaneous detection of TB and resistance to rifampicin (without further testing for isoniazid resistance), an increasing number of RR-TB cases are being detected and notified [5].”
MethodUddin, M. K. M., Ather, M. F., Akter, S., Nasrin, R., Rahman, T., Kabir, S. N., Rahman, S. M. M., Pouzol, S., Hoffmann, J., & Banu, S. (2022) · Diagnostics · doi:10.3390/diagnostics12071676 · Cited by 8
“Again, culture can detect as few as 10 colony forming units (CFU)/mL of bacilli in specimens; whereas, Xpert assay demonstrates a limit of detection of 131 CFU/mL [33,34].”
BackgroundNataraj, G., Kanade, S. R., Solanki, M., & Thombare, S. (2023) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_75_23 · Cited by 8
Analysis of Drug-Resistant Tuberculosis in Children in Shenyang, China, 2017–2021
Sun, J., Fan, L., Zhao, Y., Wu, H., Li, R., Tian, Y., Cheng, M., Ma, X., Ma, Y., Yang, X., et al. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s428720 · Cited by 8
“10,11 China is one of high DR-TB burden countries, but the epidemiological data on drug resistance in childhood TB is still lacking.”
BackgroundClassical and New Assays for Detecting Drug Resistance in Tuberculosis
Palomino, J. C., Vandamme, P. A. R., & Martin, A. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.14.73 · Cited by 8
Economic evaluations of point of care testing strategies for active tuberculosis
Zwerling, A. A., & Dowdy, D. W. (2013) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.13.27 · Cited by 9
The Prevalence of Drug-Resistant Tuberculosis among People Living with HIV (PLHIV) in Abia State
Okorie, O., Ahukanna, J., Gidado, M., Akang, G., Ubochioma, E., Rupert, E., Ibeziako, V., Meribole, E., & Osakwe, P. (2016) · Advances in Infectious Diseases · doi:10.4236/aid.2016.62009 · Cited by 8
“Gene Xpert Screening The Xpert MTB/RIF test was performed as described by (2010) [15] and [16].”
MethodEvaluation of Rifampicin-resistant Tuberculosis in Pediatric Patients by GeneXpert MTB/RIF
William, A., Rai, Y., & Ravinder, K. A. U. R. (2021) · Journal of Microbiology and Infectious Diseases · doi:10.5799/jmid.951506 · Cited by 8
Rapid cell lysis and DNA capture in a lysis microreactor
Grobler, A., Levanets, O., Whitney, S. E., Booth, C. S., & Viljoen, H. J. (2012) · Chemical Engineering Science · doi:10.1016/j.ces.2012.07.009 · Cited by 8
Mulvey, M. C., Lemmon, M. M., Rotter, S., Lees, J. P., Einck, L., & Nacy, C. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03135-14 · Cited by 8
“Rapid molecular diagnostic tests such as Xpert MTB/RIF (Cepheid) and GenoType MTBDR (Hain Lifescience) are the emerging standard for rapid INH- or RIF-resistant M. tuberculosis detection, markers of MDR-TB, because their detection thresholds from patient specimens are comparable to culture (5, 6).”
BackgroundResultInfluentialYin, F., Chan, J. F., Zhu, Q., Fu, R., Chen, J. H.-K., Choi, G. K.-Y., Tee, K., Li, L., Qian, S., Yam, W.-C., et al. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203952 · Cited by 10
Anthwal, D., Lavania, S., Gupta, R. K., Verma, A. K., Myneedu, V. P., Sharma, P. P., Verma, H., Malhotra, V., Gupta, A., Gupta, N. K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220967 · Cited by 8
Padmaja, G. V., Srujana, K., & Sadhana, C. (2019) · Journal of Dr. YSR University of Health Sciences. · doi:10.4103/jdrntruhs.jdrntruhs_46_19 · Cited by 8
“tuberculosis, which is the critical gene associated with rifampicin resistance.[9] No cross reactions have been observed with many other bacterial species tested, including a comprehensive band of mycobacteria, there by excluding non-tubercular bacteria.”
BackgroundMamaev, D. D., Khodakov, D. A., Dementieva, E., Filatov, I. V., Yurasov, D. A., Cherepanov, A. I., Vasiliskov, V. A., Smoldovskaya, O., Zimenkov, D. V., Gryadunov, D. A., et al. (2011) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683811020128 · Cited by 8
Rapid molecular detection of tuberculosis.
Heinrich, N., Rachow, A., & Höelscher, M. (2011) · PubMed · doi:10.1056/nejmc1011919 · Cited by 7
Grint, D. J., Dhillon, J., Butcher, P. D., Adams, J., Munshi, T., Witney, A. A., Gould, K. A., Laing, K. G., Cousins, C., Wasserman, S. A., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf527 · Cited by 7
Yamouni, F., Henniche, F. Z., Ifticene, M., Chabani, M., Bensersa, D., Ouadah, N. E. H., Nihad, M., & Zerouki, A. (2022) · Médecine tropicale et santé internationale · doi:10.48327/mtsi.v4i2.2024.301 · Cited by 7
Chang, Y., Zhang, M., Liu, G., Wu, X., Yan, Q., Yang, C., Liu, L., Feng, Y., & Xia, X. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00887-24 · Cited by 7
“When TB nestMIRA was tested with simulated sputum samples containing H37Rv, a 100% positive detection rate was observed at concentrations equal to or greater than 100 CFU/mL (Fig.”
InfluentialDiagnostic assessment of Xpert MTB/RIF in a sample of Mycobacterium tuberculosis Egyptian patients
Darwish, M., Wadood, M. A. E., & ALnagdi, H. (2013) · Cited by 7
Nadkarni, P. M., & Merchant, S. A. (2022) · Artificial Intelligence in Medical Imaging · doi:10.35711/aimi.v3.i3.55 · Cited by 7
Integrated Polymerase Chain Reaction Technologies (Sample-to-Answer Technologies)
Danielson, P. B., McKiernan, H. E., & Legg, K. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802971-8.00005-5 · Cited by 9
“Mutations within the rpoB gene, which confer resistance to rifampin and are often an early marker of multidrug-resistant TB, are also detected by the assay (Boehme et al., 2010; Helb et al., 2010).”
Liu, Q., Ji, Y., Martínez, L., Lu, W., Shi, X., Wang, J., & Zeng, Y. (2020) · Epidemiology and Infection · doi:10.1017/s095026882000309x · Cited by 7
“The detection limit of Xpert MTB/RIF is 5 genomic copies of purified DNA in each reaction, or 131 colony forming units per ml of MTB [5], which is significantly lower than the sputum smear microscopy and mycobacterial culture [1].”
MethodHopkins, M. J., Moorcroft, J., Correia, J. B., & Hart, I. J. (2010) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2010.00178.x · Cited by 7
Nosova, E. Y., Krasnova, M. A., Galkina, K. Y., Makarova, M. V., Litvinov, V. I., & Мороз, А. М. (2013) · Molecular Biology · doi:10.1134/s002689331301010x · Cited by 7
“The test is highly sensitive (106–176 CFU/mL) and specific (100%) for the investigation of respiratory material from different countries with high and low TB incidence [5, 6].”
BackgroundLessells, R. J., Cooke, G., McGrath, N. M., Nicol, M. P., Newell, M., & Godfrey‐Faussett, P. (2013) · Trials · doi:10.1186/1745-6215-14-170 · Cited by 7
“This is a fully automated, closed cartridge diagnostic system that utilises heminested polymerase chain reaction (PCR) and molecular beacon technology to detect the presence of Mycobacterium tuberculosis and rifampicin-resistant mutations directly from clinical samples in less than 2 h [16-18].”
MethodSauzullo, I., Rodio, D. M., Facchinetti, S., Puggioni, G., Angelis, M. D., Goldoni, P., Vullo, V., Mengoni, F., Trancassini, M., & Pietropaolo, V. (2016) · PubMed · Cited by 7
Sahebi, L., Ansarin, K., Monfaredan, A., Farajnia, S., Nili, S., & Khalili, M. (2016) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.29147 · Cited by 7
“molecular technique, as it is a high-speed method with a low risk of contamination (8-10).”
MethodNwokoye, N. N., Onubogu, C. C., Nwadike, O. P., Abiodun, A. T., Onwujekwe, O. E., Gidado, M., Olubi, O. O., Idigbe, E. O., & Olawale, O. A. (2014) · Cited by 7
Agizew, T., Boyd, R., Mathebula, U., Mathoma, A., Basotli, J., Serumola, C., Pals, S. L., Finlay, A. M., Lekone, P. E., Rankgoane-Pono, G., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234646 · Cited by 7
“The specificity among symptomatic patients with NTM positive culture, however, ranges from 92 to 99% [5–7] with a possibility of higher Xpert MTB/RIF false positivity [8].”
BackgroundRequirement of Quality Assessment for Modern Tuberculosis Laboratory Services
Şimşek, H. (2011) · Mycobacterial Diseases · doi:10.4172/2161-1068.1000101 · Cited by 7
“This system allows accurate test results with unprecedented speed, cost effective and easeof-use [31].”
BackgroundTuberculosis Diagnostics in the New Millennium: Role in TB Identification and Control
Chakravorty, S., Boehme, C. C., & Lee, J. (2012) · Tuberculosis Research and Treatment · doi:10.1155/2012/768603 · Cited by 7
Self-citationXpert MTB/RIF and pulmonary tuberculosis: time to delve deeper?
Pinto, L., & Udwadia, Z. F. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203885 · Cited by 7
Undiagnosed Active Tuberculosis in HIV‐Infected Patients Commencing Antiretroviral Therapy
Meintjes, G., & Wilkinson, R. J. (2010) · Clinical Infectious Diseases · doi:10.1086/656283 · Cited by 7
Translating Translational Research into Global Health Gains
Editors, T. P. M. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001493 · Cited by 8
“A PCR-based test built on the GeneXpert platform [12] and contained within a desktop machine that rapidly detects Mycobacterium tuberculosis, Xpert MTB/RIF can identify drug resistance in 2 hours [13].”
MethodGao, G., Zhu, C., Liu, Y., Yang, S., Xiao, J. W., Zhao, H., Yang, D., Liang, H., Wang, F., Wu, L. S., et al. (2022) · Medical Science Monitor · doi:10.12659/msm.937264 · Cited by 6
Assessment of mortality rate in tuberculosis / human immunodeficiency virus (HIV) coinfected patient
Abidemi Esther, O. J. O., Ojo, O. A., Adebajo, S. O., Ajibola, A. T., Oloyede, A. R., Popoola, H. A., Babalola, A. S., & Ojo, D. A. (2023) · Ceylon Journal of Science · doi:10.4038/cjs.v52i2.8160 · Cited by 6
Metadata
- Authors
- Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., Safi, H., Blakemore, R., Lan, N. T. N., Jones-López, E. C., Levi, M., Burday, M., Ayakaka, I., Mugerwa, R. D., McMillan, B., Winn-Deen, E., Christel, L., Dailey, P., Perkins, M. D., Persing, D. H., & Alland, D.
- Affiliations
- Rutgers New Jersey Medical School (US)
- Cepheid (United States) (US)
- Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey
- FIND (CH)
- Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
- Montefiore Medical Center (US)
- Makerere University (UG)
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 48
- Issue
- 1
- Pages
- 229-237
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2812290
- OpenAlex
- W2112022845
- Cited by
- 914
- References
- 59
- Citations by year
- 2026: 29 · 2025: 38 · 2024: 35 · 2023: 33 · 2022: 36 · 2021: 45 · 2020: 65 · 2019: 55 · 2018: 61 · 2017: 62 · 2016: 63 · 2015: 62 · 2014: 74 · 2013: 71 · 2012: 62
- FWCI
- 41.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R41AI052523, R42AI052523, R42-AI52523, R41-AI52523)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- Mycobacterium tuberculosis detection, rifampicin resistance, Xpert MTB/RIF, point-of-care testing, real-time PCR, sputum, detection limit, nontuberculous mycobacteria, retreatment tuberculosis, tuberculosis diagnosis
- MeSH terms
- Adolescent, Adult, Aged, Antitubercular Agents, Bacteriological Techniques, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Sputum, Tuberculosis, Uganda, Vietnam, Polymerase Chain Reaction, Point-of-Care Systems, Drug Resistance, Bacterial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.